{"slug":"tb-500-glp1-muscle-loss","verification":{"valid":true,"entries":15,"head":"25a5fd658a8abf2d5fad020fb800b0e18cc20c993fc7f27957fa4844e35f94ac"},"count":15,"models":["grok/grok-4.3","grok-4.3","system/audit-repair","kimi/moonshot-v1-8k","gemini/gemini-2.5-flash","fill-slots"],"yield":{"passes":15,"energy_spent_rows":0,"total_cost_usd":0.00959,"waste_cost_usd":0,"total_tokens":15510,"material_outputs":8,"usd_per_output":0.001199,"models":[{"model":"kimi/moonshot-v1-8k","passes":2,"cost_usd":0.000973,"tokens_total":6484,"outputs":5,"waste_passes":0,"usd_per_output":0.000195},{"model":"gemini/gemini-2.5-flash","passes":1,"cost_usd":0.000387,"tokens_total":3507,"outputs":3,"waste_passes":0,"usd_per_output":0.000129},{"model":"grok-4.3","passes":4,"cost_usd":0,"tokens_total":0,"outputs":0,"waste_passes":0,"usd_per_output":null},{"model":"system/audit-repair","passes":4,"cost_usd":0,"tokens_total":0,"outputs":0,"waste_passes":0,"usd_per_output":null},{"model":"fill-slots","passes":2,"cost_usd":0,"tokens_total":0,"outputs":0,"waste_passes":0,"usd_per_output":null},{"model":"grok/grok-4.3","passes":2,"cost_usd":0.00823,"tokens_total":5519,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T08:41:04.697Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"TB-500 and GLP-1 Agonist-Associated Lean Mass Changes: Evidence Mapping","register":"source_ledger","body":"## GLP-1 Agonists and Lean Mass Reduction\n\nClinical trials document that weight loss with GLP-1 receptor agonists includes a lean mass component. In the STEP 1 trial of semaglutide, lean mass accounted for approximately 45% of total weight loss. In SURMOUNT-1 with tirzepatide, the fraction was approximately 26% (human tier).\n\n## TB-500 Mechanism of Action\n\nTB-500 is a synthetic fragment of thymosin beta-4 that promotes actin sequestration, facilitating cell migration to sites of injury and supporting angiogenesis (mechanistic tier). Production of endogenous thymosin beta-4 declines with age (mechanistic tier).\n\n## Preclinical Evidence on Tissue Repair\n\nRat full-thickness wound models showed thymosin beta-4 accelerated closure and improved tissue organization (preclinical tier). Animal studies of muscle, tendon, and ligament injury indicate faster recruitment of repair cells and reduced inflammation persistence (preclinical tier). No specific 30-50% quantitative acceleration figure is established across studies.\n\n## Human Data on TB-500 / Thymosin Beta-4\n\nPhase 1 and Phase 2 trials in dermal wounds, corneal injury, and cardiac contexts report good tolerability with no serious adverse events attributed to the peptide (human tier). No completed Phase 2 or 3 trials exist for skeletal muscle preservation or GLP-1-associated lean mass changes (human tier: absence of data). Most musculoskeletal observations remain limited to animal models.\n\n## Mapping to GLP-1 Context\n\nNo published human or animal studies directly examine TB-500 with GLP-1 agonists. Any potential interaction with muscle repair during caloric deficit is speculative (speculative tier). TB-500 is described as supporting repair cell mobilization rather than anabolic hypertrophy.\n\n## Evidence Gaps\n\nLarge-scale human trials for musculoskeletal applications of TB-500 are absent. All claims regarding GLP-1 muscle loss mitigation remain outside existing datasets.","claims":[{"id":"c1","text":"In STEP 1, lean mass loss was ~45% of total weight lost on semaglutide.","section":"GLP-1 Agonists and Lean Mass Reduction","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes baseline human data on indiscriminate lean loss.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"extra":{}},{"id":"c2","text":"In SURMOUNT-1, lean mass loss fraction was ~26% on tirzepatide.","section":"GLP-1 Agonists and Lean Mass Reduction","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Documents variable lean loss across GLP-1 agents.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"extra":{}},{"id":"c3","text":"Thymosin beta-4 promotes cell migration via actin regulation and supports angiogenesis.","section":"TB-500 Mechanism of Action","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Core repair-cell mobilization mechanism.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"extra":{}},{"id":"c4","text":"Rat wound models demonstrate accelerated closure with thymosin beta-4.","section":"Preclinical Evidence on Tissue Repair","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Direct animal healing data separating from human.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"extra":{}},{"id":"c5","text":"Phase 1/2 human trials of thymosin beta-4 report good tolerability and no serious peptide-attributable adverse events in wound and cardiac indications.","section":"Human Data on TB-500 / Thymosin Beta-4","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Documents existing human safety evidence base.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"extra":{}},{"id":"c6","text":"No human trials examine TB-500 with GLP-1 agonists or for lean mass preservation during GLP-1 therapy.","section":"Evidence Gaps","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Plain statement of data absence.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.067676","title":"Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonist Effects","quote":"Semaglutide has been associated with loss of lean mass up to 40% of total weight loss... In STEP 1... yielding a fraction of weight lost from lean mass of 45.5%. ... SURMOUNT-1... yielding a fraction of weight lost from lean mass of 25.7%.","link_status":"http_403","quote_status":"unverified"},{"id":"s2","type":"review","url":"https://www.innerbody.com/thymosin-beta-4-and-tb-500","title":"TB4 and TB-500 Peptide Therapy | What to Know in 2026","quote":"A phase 1 safety study in healthy volunteers demonstrated that recombinant thymosin beta-4 was well tolerated... no dose-limiting toxicities or serious adverse events... Early human trials show it is safe and biologically active.","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/10469335/","title":"Thymosin beta4 accelerates wound healing","quote":"we investigated whether the angiogenic thymic peptide thymosin beta4 (Tbeta4) enhanced wound healing in a rat full thickness wound model.","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":0,"tokens_out":0,"prev_hash":"genesis","hash":"0fbd0bd3e2f2eee3e6eb1234364982395a0945731ca80c4c1bc3195637367421"},{"seq":1,"id":"k2","ts":"2026-06-29T10:07:08.025Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s4","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41476424/","title":"Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians","quote":"TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking, and both remain banned substances in sports.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"medical","url":"https://formblends.com/articles/peptide-hub/tb-500-with-glp-1-best-protocol","title":"TB-500 with GLP-1: Best Protocol","quote":"TB-500 supports the musculoskeletal system by accelerating repair of exercise-induced damage, helping patients maintain consistent training schedules.","link_status":"ok","quote_status":"verified"},{"id":"s6","type":"medical","url":"https://peptiq.io/blog/peptide-stacking-muscle-preservation-glp1","title":"Peptide Stacking for Muscle Preservation on GLP-1s: The Complete Protocol","quote":"Research demonstrates TB-500 reduces muscle cell apoptosis (programmed death) under stress conditions, including caloric deficit. Users running GLP-1s alongside TB-500 consistently report better muscle retention and faster recovery from resistance training.","link_status":"ok","quote_status":"verified"},{"id":"s7","type":"reddit","url":"https://www.reddit.com/r/crossfit/comments/1m6zca5/thoughts_on_bpc157/","title":"Thoughts on BPC-157?","quote":"The last few weeks have shown pretty significant reduction in pain since I added TB-500.","link_status":"ok","quote_status":"unverified"},{"id":"s8","type":"other","url":"https://glp1forum.com/threads/bpc157-tb500.13222/","title":"BPC157/TB500","quote":"Now - i cant train until i get this sorted and it heals without surgery, but i am running GH to help heal it, as well as our friend BPC157/TB500","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"prev_hash":"0fbd0bd3e2f2eee3e6eb1234364982395a0945731ca80c4c1bc3195637367421","hash":"2c1767e2d42fdf5c4ddcbd2fc75d8db73143e5906a9d51260d0c4b26b5e4ca2f"},{"seq":2,"id":"k3","ts":"2026-06-29T10:07:38.390Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s9","type":"medical","url":"https://denverregenerativemedicine.com/wolverine-peptide-stack-injury-recovery-gh-restoration-glp1/","title":"The Wolverine Peptide Stack: A Clinical Guide for Injury Recovery, GH Restoration, and Muscle Preservation on GLP-1s","quote":"GLP-1 medications like Semaglutide are clinically associated with lean muscle loss alongside fat loss; the Wolverine stack may help offset this when combined with adequate protein intake and resistance training.","link_status":"ok","quote_status":"unverified"},{"id":"s10","type":"medical","url":"https://delawareintegrativemedicine.com/glp-1/","title":"GLP-1 | Delaware Integrative Medicine","quote":"To amplify these benefits, we harness the synergistic and complimentary effects of pairing GLP-1 with BCP-157 and TB-500 peptides. This strategic combination optimizes fat loss while preserving valuable muscle mass, paving the way for sustainable weight management and a healthier lifestyle.","link_status":"ok","quote_status":"verified"},{"id":"s11","type":"other","url":"https://www.redfoxpeptides.is/best-peptides-to-stack-with-tirzepatide/","title":"5 Best Peptides to Stack With Tirzepatide for Weight Loss","quote":"TB-500 provides systemic recovery support, reducing inflammation and improving flexibility during exercise protocols.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"prev_hash":"2c1767e2d42fdf5c4ddcbd2fc75d8db73143e5906a9d51260d0c4b26b5e4ca2f","hash":"18035b1d42ab745dd11547abf1df71f01b82b8a2c6b8f72b81f24138e2fb29dc"},{"seq":3,"id":"k4","ts":"2026-06-29T12:47:36.641Z","model":"system/audit-repair","role":"claim_post","action":"claim","payload":{"claim_id":"c7","tier":"system","text":"TB-500 and GLP-1 Agonist-Associated Lean Mass Changes: Evidence Mapping is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","who_claims":"miscsubjects protocol","source_ids":[],"slot":"what_it_is","posted_by":{"actor":"miscsubjects protocol","channel":"protocol/fill-slots","ts":"2026-06-29T12:47:36.641Z","model":"system/audit-repair","rationale":""}},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"18035b1d42ab745dd11547abf1df71f01b82b8a2c6b8f72b81f24138e2fb29dc","hash":"4f33354034c422541284d06efc2da1b68361107c365c537d2ed3e641b2459393"},{"seq":4,"id":"k5","ts":"2026-06-29T12:47:36.672Z","model":"system/audit-repair","role":"claim_post","action":"claim","payload":{"claim_id":"c8","tier":"preclinical","text":"Per this ledger on TB-500 and GLP-1 Agonist-Associated Lean Mass Changes: Evidence Mapping: 8 scientific and 1 anecdotal sources are catalogued; 1 preclinical claim(s) summarize animal/cell literature in-catalogue.","who_claims":"miscsubjects ledger synthesis","source_ids":[],"slot":"what_is_known","posted_by":{"actor":"miscsubjects ledger synthesis","channel":"protocol/fill-slots","ts":"2026-06-29T12:47:36.672Z","model":"system/audit-repair","rationale":""}},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"4f33354034c422541284d06efc2da1b68361107c365c537d2ed3e641b2459393","hash":"c26bf31d3b9a69ada9f8271489b89657bcdb167c0f9959f4d86d52c624414f22"},{"seq":5,"id":"k6","ts":"2026-06-29T12:47:36.702Z","model":"system/audit-repair","role":"claim_post","action":"claim","payload":{"claim_id":"c9","tier":"mechanistic","text":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","who_claims":"miscsubjects protocol","source_ids":[],"slot":"limitations","posted_by":{"actor":"miscsubjects protocol","channel":"protocol/fill-slots","ts":"2026-06-29T12:47:36.702Z","model":"system/audit-repair","rationale":""}},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"c26bf31d3b9a69ada9f8271489b89657bcdb167c0f9959f4d86d52c624414f22","hash":"b65624c7c4e9e6aad461e02e078f427079b2b98529ca4355adbfd9048be2a488"},{"seq":6,"id":"k7","ts":"2026-06-29T12:47:36.739Z","model":"system/audit-repair","role":"claim_post","action":"claim","payload":{"claim_id":"c10","tier":"human","text":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","who_claims":"miscsubjects protocol","source_ids":[],"slot":"disclaimer","posted_by":{"actor":"miscsubjects protocol","channel":"protocol/fill-slots","ts":"2026-06-29T12:47:36.739Z","model":"system/audit-repair","rationale":""}},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"b65624c7c4e9e6aad461e02e078f427079b2b98529ca4355adbfd9048be2a488","hash":"4476e5b3bcadbe8813152926f7e373824bcef63b1515f49456a6830cd31b5bec"},{"seq":7,"id":"k8","ts":"2026-06-29T12:55:07.456Z","model":"kimi/moonshot-v1-8k","role":"collaborator","action":"collaborate","payload":{"claims_added":["c19","c20"],"challenge_id":null,"rationale":"I am adding explicit claims about gaps in knowledge and identifying who claims what from anecdotes as per the instructions. I am not Grok because I am adding new claims based on the existing topology and instructions, rather than challenging existing claims."},"rationale":"I am adding explicit claims about gaps in knowledge and identifying who claims what from anecdotes as per the instructions. I am not Grok because I am adding new claims based on the existing topology and instructions, rather than challenging existing claims.","tokens_in":2860,"tokens_out":322,"cost":0.0004773,"prev_hash":"4476e5b3bcadbe8813152926f7e373824bcef63b1515f49456a6830cd31b5bec","hash":"769642d6306ace9afab7a0d71af4cfea6c1f20e1bd2afc59d1c7e073a4c3362f"},{"seq":8,"id":"k9","ts":"2026-06-29T12:56:11.668Z","model":"kimi/moonshot-v1-8k","role":"collaborator","action":"collaborate","payload":{"claims_added":["c21","c22"],"challenge_id":"c23","rationale":"I am adding explicit gaps in knowledge regarding the interaction between TB-500 and GLP-1 agonists, as well as naming sources from anecdotes which were not explicitly attributed in the claims."},"rationale":"I am adding explicit gaps in knowledge regarding the interaction between TB-500 and GLP-1 agonists, as well as naming sources from anecdotes which were not explicitly attributed in the claims.","tokens_in":2860,"tokens_out":442,"cost":0.0004953000000000001,"prev_hash":"769642d6306ace9afab7a0d71af4cfea6c1f20e1bd2afc59d1c7e073a4c3362f","hash":"f83d286cfeb386d62019aa0b58f389df901656cf5192a6f5e716eb3088f3f672"},{"seq":9,"id":"k10","ts":"2026-06-29T14:20:55.685Z","model":"gemini/gemini-2.5-flash","role":"collaborator","action":"collaborate","payload":{"claims_added":["c24","c25"],"challenge_id":"c26","rationale":"As Gemini, I've added two tier-honest claims to the ledger, focusing on 'who_claims_what' from 'medical' and 'other' type sources that were previously unused. This addresses the instruction to name who claims what from anecdotes if missing and fills gaps in attributing specific claims to their sources. I also challenged a claim's tier to improve the ledger's accuracy regarding evidence strength, as per the prompt's allowance for challenging weak claims. I am not Grok."},"rationale":"As Gemini, I've added two tier-honest claims to the ledger, focusing on 'who_claims_what' from 'medical' and 'other' type sources that were previously unused. This addresses the instruction to name who claims what from anecdotes if missing and fills gaps in attributing specific claims to their sources. I also challenged a claim's tier to improve the ledger's accuracy regarding evidence strength, as per the prompt's allowance for challenging weak claims. I am not Grok.","tokens_in":2955,"tokens_out":552,"cost":0.00038722500000000005,"prev_hash":"f83d286cfeb386d62019aa0b58f389df901656cf5192a6f5e716eb3088f3f672","hash":"e381811e1ebf656cdce9eab77ac4920a13e3b46b8791c0989e4d0eb27b584629"},{"seq":10,"id":"k11","ts":"2026-06-29T14:21:52.255Z","model":"grok/grok-4.3","role":"editor","action":"synthesize_body","payload":{"chars":5004,"claims_used":10,"legibility":{"pass":true,"reasons":[]}},"rationale":"Reader body rewritten from ranked ledger topology — plain English","tokens_in":4454,"tokens_out":1065,"cost":0.00823,"prev_hash":"e381811e1ebf656cdce9eab77ac4920a13e3b46b8791c0989e4d0eb27b584629","hash":"9f008774aed3b0b9eede2a695a05e063dc45522915ba82b68930975511976e53"},{"seq":11,"id":"k12","ts":"2026-06-29T17:20:36.750Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s12","type":"reddit","url":"https://www.reddit.com/r/NTNPerformance/comments/1tc5a9d/peptide_stacking_cheat_sheet_what_goes_together/","title":"Peptide stacking cheat sheet. What goes together and why","quote":"The biggest risk on any GLP-1 cut is losing muscle along with fat. GH support may help protect against that especially when combined with high protein and training. ... TB-500 is studied for broader soft tissue remodeling and mobility .","link_status":"ok","quote_status":"unverified"},{"id":"s13","type":"reddit","url":"https://www.reddit.com/r/workout/comments/1tg0egc/peptides_for_faster_recovery/","title":"Peptides for faster recovery","quote":"TB-500 don't accelerate recovery from injury as many claim. They minimize inflammation and reduce pain. semaglutide”. Which means 35-40% of the ... You lose muscle mass as well as fat.","link_status":"ok","quote_status":"unverified"},{"id":"s14","type":"reddit","url":"https://www.reddit.com/r/GLP1microdosing/comments/1su5b47/physician_perspective_microdosing_glp1s_for/","title":"microdosing GLP-1s for maintenance and what I'm seeing ...","quote":"TB-500 is more systemic — muscle, joint, inflammation . For chronic skeletal issues like yours, TB-500 might be worth exploring with your ...","link_status":"ok","quote_status":"unverified"},{"id":"s15","type":"reddit","url":"https://www.reddit.com/r/BodyHackGuide/comments/1k0ndxq/the_musclesaving_stack_for_glp1_users_dont_let/","title":"💪 The Muscle-Saving Stack for GLP-1 Users (Don’t Let Fat Loss Kill Your Gains)","quote":"GLP-1s like Tirzepatide, Retatrutide, and Semaglutide ... can indirectly cause muscle loss ... 3. BPC-157 + TB-500 • Keeps joints, tendons, and soft tissue resilient • I microdose 2x/week to avoid injury while cutting heavy","link_status":"ok","quote_status":"unverified"},{"id":"s16","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/14zorm9/semaglutide_reduces_muscle_mass/","title":"Semaglutide reduces muscle mass?","quote":"In one of the GLP-1 clinical trials people lost 0.4 pounds of muscle for every pound of fat lost . That was somewhat concerning because that ...","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"9f008774aed3b0b9eede2a695a05e063dc45522915ba82b68930975511976e53","hash":"6929ef67859851c2f45935489d6e11b32f1cb9419c5c69b3948f449183267c75"},{"seq":12,"id":"k13","ts":"2026-06-29T17:21:06.886Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s17","type":"reddit","url":"https://www.reddit.com/r/ACL/comments/1jwe0oe/documenting_my_aclr_meniscus_repair_journey/","title":"Documenting My ACLR + Meniscus Repair Journey – Trying the “Wolverine Stack” (BPC-157 + TB-500)","quote":"I started taking BPC-157 and TB-500 —a combo often called the “Wolverine Stack”—to help support my recovery.","link_status":"ok","quote_status":"unverified"},{"id":"s18","type":"reddit","url":"https://www.reddit.com/r/tirzepatidecompound/comments/1igpatr/to_everyone_freaking_out_about_muscle_wasting/","title":"To everyone freaking out about “muscle wasting”...","quote":"71F and stacking T & R and BCP157/TB500. I need muscles too!","link_status":"ok","quote_status":"unverified"},{"id":"s19","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1t95zs0/peptides_cheatsheet/","title":"peptides cheatsheet","quote":"TB-500 – cuts down inflammation, helps muscle repair and flexibility. ... Wolverine (BPC + TB-500) – soft tissue and recovery","link_status":"ok","quote_status":"unverified"},{"id":"s20","type":"reddit","url":"https://www.reddit.com/r/crossfit/comments/1pv5qpz/peptides_are_all_hype/","title":"Peptides are all hype?","quote":"After hearing all the hype around peptides, specifically from Andrew Hiller and the Sevan crew, I gave TB500 /BPC-157 a try for 90 days.","link_status":"ok","quote_status":"unverified"},{"id":"s21","type":"x","url":"https://x.com/gr8tful88/status/2071404994192974208","title":"peptides stack post","quote":"Muscle recovery: BPC-157, TB-500. Repair tendons, ligaments, and soft tissue damage faster than rest alone. ... Fat loss: Semaglutide, Tirzepatide, GLP-1 agonists suppress appetite","link_status":"ok","quote_status":"unverified"},{"id":"s22","type":"x","url":"https://x.com/peptivaresearch/status/2067779091047043553","title":"Best Peptide Stack for Fat Loss & Muscle Retention","quote":"The Best Peptide Stack for Fat Loss & Muscle Retention ✅ GLP-1s (Tirzepatide, Retatrutide) - Suppress hunger & force fat loss. ✅GH Peptides ... ✅BPC-157 + TB-500 - Keep joints & tendons healthy.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"6929ef67859851c2f45935489d6e11b32f1cb9419c5c69b3948f449183267c75","hash":"f64f70d4b5cb3a70940fae03cb106c5b437dc28943f08a64071a2830ef813749"},{"seq":13,"id":"k14","ts":"2026-06-29T20:28:05.462Z","model":"fill-slots","role":"claim_post","action":"claim","payload":{"claim_id":"c38","tier":"system","text":"TB-500 and GLP-1 Agonist-Associated Lean Mass Changes: Evidence Mapping is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","who_claims":"miscsubjects protocol","source_ids":[],"slot":"what_it_is","posted_by":{"actor":"miscsubjects protocol","channel":"protocol/fill-slots","ts":"2026-06-29T20:28:05.462Z","model":"fill-slots","rationale":""}},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"f64f70d4b5cb3a70940fae03cb106c5b437dc28943f08a64071a2830ef813749","hash":"b3686cbe80b67ab0ce1a856aa80f5bb6e7d5b36d28be581ecabfa1f0f7797b22"},{"seq":14,"id":"k15","ts":"2026-06-29T20:28:06.909Z","model":"fill-slots","role":"claim_post","action":"claim","payload":{"claim_id":"c39","tier":"mechanistic","text":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","who_claims":"miscsubjects protocol","source_ids":[],"slot":"limitations","posted_by":{"actor":"miscsubjects protocol","channel":"protocol/fill-slots","ts":"2026-06-29T20:28:06.909Z","model":"fill-slots","rationale":""}},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"b3686cbe80b67ab0ce1a856aa80f5bb6e7d5b36d28be581ecabfa1f0f7797b22","hash":"25a5fd658a8abf2d5fad020fb800b0e18cc20c993fc7f27957fa4844e35f94ac"}]}